Assenagon Asset Management S.A. Sells 92 Shares of Humana Inc. (NYSE:HUM)

Assenagon Asset Management S.A. lowered its position in Humana Inc. (NYSE:HUMFree Report) by 2.2% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,141 shares of the insurance provider’s stock after selling 92 shares during the quarter. Assenagon Asset Management S.A.’s holdings in Humana were worth $2,015,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the company. State Street Corp lifted its stake in Humana by 2.5% in the second quarter. State Street Corp now owns 5,852,050 shares of the insurance provider’s stock valued at $2,621,731,000 after acquiring an additional 143,883 shares during the last quarter. Capital World Investors raised its position in shares of Humana by 18.7% in the second quarter. Capital World Investors now owns 2,322,684 shares of the insurance provider’s stock valued at $1,038,513,000 after purchasing an additional 366,007 shares during the period. Geode Capital Management LLC raised its position in shares of Humana by 2.6% in the second quarter. Geode Capital Management LLC now owns 2,293,170 shares of the insurance provider’s stock valued at $1,022,332,000 after purchasing an additional 58,693 shares during the period. Morgan Stanley raised its position in shares of Humana by 20.8% in the fourth quarter. Morgan Stanley now owns 1,688,442 shares of the insurance provider’s stock valued at $864,804,000 after purchasing an additional 290,865 shares during the period. Finally, Norges Bank bought a new position in shares of Humana in the fourth quarter valued at about $690,516,000. Institutional investors and hedge funds own 91.86% of the company’s stock.

Humana Trading Up 0.8 %

HUM opened at $378.87 on Friday. The company’s 50 day moving average is $447.86 and its 200-day moving average is $474.36. Humana Inc. has a 1-year low of $342.69 and a 1-year high of $541.21. The company has a current ratio of 1.59, a quick ratio of 1.37 and a debt-to-equity ratio of 0.63. The company has a market cap of $46.64 billion, a P/E ratio of 19.12, a PEG ratio of 2.21 and a beta of 0.46.

Humana (NYSE:HUMGet Free Report) last posted its quarterly earnings results on Thursday, January 25th. The insurance provider reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.87). Humana had a net margin of 2.34% and a return on equity of 19.44%. The company had revenue of $26.46 billion during the quarter, compared to analyst estimates of $25.47 billion. During the same quarter in the previous year, the business posted $1.62 earnings per share. The company’s revenue for the quarter was up 17.9% on a year-over-year basis. Equities research analysts predict that Humana Inc. will post 16.04 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on HUM shares. Oppenheimer reissued an “outperform” rating and issued a $630.00 price objective on shares of Humana in a research report on Wednesday, January 17th. Mizuho lowered their price target on shares of Humana from $550.00 to $400.00 and set a “buy” rating on the stock in a research report on Friday, January 26th. JPMorgan Chase & Co. lowered their price target on shares of Humana from $593.00 to $575.00 and set a “neutral” rating on the stock in a research report on Friday, November 17th. Argus raised shares of Humana from a “hold” rating to a “buy” rating and set a $550.00 price target on the stock in a research report on Tuesday, December 12th. Finally, Truist Financial reaffirmed a “hold” rating and set a $550.00 price target on shares of Humana in a research report on Friday, January 19th. Seven investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to MarketBeat, Humana presently has an average rating of “Moderate Buy” and an average price target of $513.85.

View Our Latest Stock Analysis on HUM

About Humana

(Free Report)

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

See Also

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.